

## CADTH REIMBURSEMENT REVIEW

# Stakeholder Feedback on Draft Recommendation

**galcanezumab (Emgality)**  
(Eli Lilly Canada Inc.)

**Indication:** Prevention of migraine

**December 2, 2021**

**Disclaimer:** The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting stakeholder group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.

# CADTH Reimbursement Review

## Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	SR0693
Name of the drug and Indication(s)	Galcanezumab (Emgality) for the prevention of migraine in adults who have at least four migraine days per month
Organization Providing Feedback	FWG

1. Recommendation revisions		
Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.		
Request for Reconsideration	Major revisions: A change in recommendation <b>category</b> or patient <b>population</b> is requested	<input type="checkbox"/>
	Minor revisions: A change in reimbursement <b>conditions</b> is requested	<input type="checkbox"/>
No Request for Reconsideration	Editorial revisions: Clarifications in recommendation <b>text</b> are requested	X
	No requested revisions	<input type="checkbox"/>

2. Change in recommendation category or conditions
Complete this section if major or minor revisions are requested
Please identify the specific text from the recommendation and provide a rationale for requesting a change in recommendation.

3. Clarity of the recommendation
Complete this section if editorial revisions are requested for the following elements
<b>a) Recommendation rationale</b>
Please provide details regarding the information that requires clarification.
<b>b) Reimbursement conditions and related reasons</b>
Please provide details regarding the information that requires clarification.
<b>c) Implementation guidance</b>
<ul style="list-style-type: none"> <li>Specify acceptable oral prophylactic therapies (e.g., beta blockers, candesartan, amitriptyline, venlafaxine, sodium valproate/divalproex sodium, topiramate, gabapentin, etc.), adequacy of dosing and trial duration.</li> </ul>

- Clarify whether consideration can be given for renewals in patients who had an initial adequate response, discontinued therapy as renewal criteria was not met subsequently, then relapsed?
- Provide additional context around the statement that ‘Galcanezumab should not be used in combination with onabotulinumtoxinA.’ Is it that it should not be used in combination with Botox, or that it is not cost effective to use with Botox? Or is it that there is no data supporting combination use with Botox?

## Outstanding Implementation Issues

In the event of a positive draft recommendation, drug programs can request further implementation support from CADTH on topics that cannot be addressed in the reimbursement review (e.g., concerning other drugs, without sufficient evidence to support a recommendation, etc.). Note that outstanding implementation questions can also be posed to the expert committee in Feedback section 4c.

Algorithm and implementation questions
<b>1. Please specify sequencing questions or issues that should be addressed by CADTH (oncology only)</b>
1. 2.
<b>2. Please specify other implementation questions or issues that should be addressed by CADTH</b>
1. 2.
Support strategy
<b>3. Do you have any preferences or suggestions on how CADTH should address these issues?</b>
May include implementation advice panel, evidence review, provisional algorithm (oncology), etc.